Drug Profile
Mometasone eluting resorbable scaffold - Lyra Therapeutics
Alternative Names: LYR-210; LYR-220; Mometasone furoate sinus drug depotLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator 480 Biomedical
- Developer Lyra Therapeutics
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated hydrocarbons; Furans; Glucocorticoids; Phenanthrenes; Pregnadienediols; Skin disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Rhinosinusitis
Most Recent Events
- 21 Mar 2024 Lyra Therapeutics expects end of phase II meeting for LYR 220 with US FDA in the second half of 2024
- 12 Sep 2023 Efficacy and adverse events data from a phase II BEACON trial in Rhinosinusitis released by Lyra Therapeutics
- 30 Aug 2023 Lyra Therapeutics completes a phase II BEACON trial for Rhinosinusitis (Intranasal) in USA, Australia (NCT05035654)